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Monitoring of renal graft status through peripheral
blood (PB) rather than invasive biopsy is important as
it will lessen the risk of infection and other stresses,
while reducing the costs of rejection diagnosis. Blood
gene biomarker panels were discovered by microar-
rays at a single center and subsequently validated and
cross-validated by QPCR in the NIH SNSO1 randomized
study from 12 US pediatric transplant programs. A to-
tal of 367 unique human PB samples, each paired with
a graft biopsy for centralized, blinded phenotype clas-
sification, were analyzed (115 acute rejection (AR), 180
stable and 72 other causes of graft injury). Of the dif-
ferentially expressed genes by microarray, Q-PCR anal-
ysis of a five gene-set (DUSP1, PBEF1, PSEN1, MAPK9
and NKTR) classified AR with high accuracy. A logistic
regression model was built on independent training-
set (n = 47) and validated on independent test-set
(n = 198)samples, discriminating AR from STA with
91% sensitivity and 94% specificity and AR from all
other non-AR phenotypes with 91% sensitivity and
90% specificity. The 5-gene set can diagnose AR po-
tentially avoiding the need for invasive renal biopsy.
These data support the conduct of a prospective study
to validate the clinical predictive utility of this diagnos-
tic tool.
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The accurate and timely diagnosis of acute renal allograft
rejection (AR) is necessary to optimize immunosuppres-
sive drug management and preserve renal function in kid-
ney transplant recipients. Unfortunately, the methods of
diagnosis remain imperfect. Since many conditions other
than AR lead to renal allograft dysfunction, the diagnosis
of AR cannot be made on functional grounds alone and
requires confirmation using a kidney biopsy. Although, the
diagnostic biopsy criteria for AR have been codified over
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time (1), the diagnosis using biopsy process remains lim-
ited by sampling error, assessment variability, procedural
morbidity and cost. Additionally, renal allograft dysfunction
is a relatively insensitive means of detecting early AR; ap-
proximately 10% of patients with clinically normal renal
function are found to have evidence of AR on surveillance
biopsy (2). Ideally, a less-invasive means for diagnosing
AR, could be used for surveillance of transplant recipients,
thereby reducing the need for biopsy and providing a more
efficient means of immune management of graft injury.
Transcriptional profiling studies on renal allograft biopsy
specimens have demonstrated substantial, coordinated ex-
pression changes in many genes that uniquely identify pa-
tients with established AR, as well as other conditions in
the differential diagnosis for allograft dysfunction (3–6). In
general, these changes are related to the inflammatory in-
filtrate resident cells within the kidney, and associated tran-
scriptional changes in renal tissue. However, when these
studies have been applied to peripheral blood (PB) (7,8),
the diagnostic changes related to AR have been less ev-
ident, presumably due to a reduced signal to noise ratio
inherent in a site remote from the allograft (9).
In order to increase the sensitivity and specificity of detec-
tion for relatively rare biomarkers within molecularly het-
erogeneous samples such as PB, we employed a carefully
designed methodological approach to integrate the tran-
scriptional profiles of PB samples from patients with and
without biopsy-proven AR from three different microarray
platforms. Changes in PB transcriptional profiles were cor-
related with biopsy-proven AR, and used to distinguish AR
from other common conditions arising in kidney transplant
patients. The examination of changes across a highly reg-
ulated set of genes was used to assess their utility for the
noninvasive diagnosis of AR and a diagnostic alternative to
the invasive renal biopsy.
Methods
Patient and sample information
And 367 PB samples from 236 unique pediatric and young adult kidney
transplant recipients were enrolled (as shown in Figure 1). Within this co-
hort, 137 patients were enrolled from Stanford University for discovery and
validation, and 99 patients from the NIH/NIAID prospective study from 12
US transplant centers, “Suppressing the Immune System With or With-
out Steroids in Children Who Have Received Kidney Transplants”(SNS01;
NCT00141037; ClinicalTrials.gov) were enrolled for independent external
validation (complete clinical data from the SNS study is discussed else-
where in Sarwal et al. (10). The study was governed by IRB approval and
informed consent.
Each PB sample in this study was paired with a contemporary renal allograft
biopsy (within 48 hours) from the same patient. Surveillance biopsies were
obtained from all patients at engraftment, 3, 6, 12 and 24 months post-
transplantation and additionally at the times of suspected graft dysfunction
(for SNS clinical study details see Sarwal et al. [10]; for SNS histology study
details see Naesens et al. [11]). Multiple PB-biopsy pairs from the same
patient were utilized as long as each biopsy had a conclusive phenotypic
diagnosis. Each biopsy was scored by the center pathologist for each en-
rolling clinical site; but given the possibility of discordance in biopsy reads
across centers, all biopsies were blindly rescored by a single central pathol-
ogist using to the Banff (12) classification (complete SNS histology data in
Naesens et al. [11]). The PB-biopsy pairs were categorized as “acute rejec-
tion” (AR; n = 115), or as “stable” (STA, n = 180), if there was absence
of AR and any other substantial pathology. A third category of PB-biopsy
pairs were characterized as “non-AR/non-STA” (n = 72) if they exhibited no
evidence of Banff graded AR, but either met the Banff criteria for “border-
line” classification (n = 12), had a diagnosis of chronic allograft nephropathy
(CAN; samples had IFTA grade ≥ 1; n = 37), or chronic calcineurin inhibitor
toxicity (CNIT; n = 16), or bacterial/viral infection or other undefined chronic
graft injury (n = 7).
Sample collection, RNA extraction, microarray hybridization and
analysis
Blood was collected in 2.5 mL PAXgeneTM Blood RNA Tubes (PreAna-
lytiX, Qiagen) or in Ficoll tubes for peripheral blood (PBL) isolation (the
latter samples were only used for microarray discovery on Affymetrix). To-
tal RNA was extracted using a previously published protocol9. Our goal
was to maximize the power of discovering a robust gene-set for AR, and
to minimize platform specific artifacts (e.g., issues of cross-hybridization
(13), specificity of hybridization (14), globin gene effect9 of whole blood
on the Affymetrix platform, differential stability of Cy dyes (15), platform
specific bias). Furthermore, because each array platform uses different sets
of genes that are represented by different probe set IDs, we used AILUN
(http://ailun.stanford.edu) (16) to re-annotate the probe set IDs with the cur-
rent Entrez Gene IDs. All Gene expression values were transformed to log2
for further analysis. We applied significance analysis of microarrays (SAM)
(17) to identify differentially expressed genes for AR on all 3 platforms, with
a threshold false discovery rate (FDR) < 5%.
Quantitative polymerase chain reaction (Q-PCR)
Standard protocols were used for Q-PCR reactions on the ABI 7900 Se-
quence Detection System (Applied Biosystems, Foster City, CA) under stan-
dard cycle conditions (10 min at 95◦C, 40 cycles of 15s 95◦C, 30 s at 60◦C),
using gene expression assays (Applied Biosystems, Foster City, CA). The
relative amount of RNA expression was calculated using a comparative CT
method. Expression values were normalized to 18S using ribosomal RNA
endogenous reference and universal RNA (Agilent Inc., Santa Clara; Cat
#740000).
Biological pathway and cell specific expression analysis
We used Ingenuity Pathway Analysis (IPA) to identify significant signaling
pathways. We chose -log10P > 1.3 as a threshold for identifying significant
pathways in IPA. We used BioGPS (18,19) to identify the blood cell types
in which the differentially expressed genes were highly expressed. A gene
was highly expressed in a blood cell type if its expression in a given blood
cell type was greater than 10 times its median expression over all tissues.
We used hypergeometric test to determine whether the proportion of the
highly expressed genes in each cell type was statistically significant or
not. The p-values from hypergeometric test were corrected for multiple
hypotheses using Benjamini–Hochberg correction.
Building a five-gene classification model for diagnosis of acute
rejection
A schematic outline of the study is presented in Figure 1 and shows the
number of samples used for discovery by microarrays (122 PB), verification
by QPCR (34 PB), building an AR logistic regression model by penalized
maximum likelihood method, in an independent sample set by QPCR (47
PB) and testing the performance of the model in the SNS clinical study (198
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Figure 1: Summary of Study Design. The gene-based biomarker discovery pipeline for an AR blood test follows a path of (a) discovery
by microarrays across 3 different platforms across a defined set (n = 103) of AR and STA blood samples; followed by (b) verification
(n = 34) and validation (n = 47) on independent AR and STA blood samples; and (c) prediction of AR (n = 198) in other varying phenotypes
of graft injury likely to be encountered in an outpatient clinical setting. Array data generated from the three platforms were compared
by mapping the transcripts to Entrez Gene identifiers. Common genes regulated significantly in AR on each platform were identified
using a common significance threshold (SAM; FDR<5%). A total of 122 microarrays were run on 103 unique samples. 19 samples were
used for correlation of within sample data, across the three different platforms. A 32-gene set was selected for initial verification on 34
samples (Verification Set containing 17 AR and 17 STA) chosen from the samples used on the microarrays and a significant set of 5 genes
(p < 0.05) were further validated in 47 independent samples from Stanford University for development of a 5-gene model by logistic
regression analysis (Training Set containing 23 AR and 24 STA samples). This locked regression model generated using the 5 genes was
applied to the second independent set of 198 samples (Test Set containing 32 AR, 94 STA and 72 nonAR/nonSTA clinical phenotypes)
from SNSO1, for accurate AR classification. Raw microarray data are available in NCBI GEO under Accession No. GSE14067.
PB). Summary statistics for patient demographic and clinical variables are
provided in Table 1.
The 5-gene model was validated in a second independent cohort of 198
samples from SNS01 (Test Set). The Test set consisted of blood samples
collected at the time of biopsy confirmed AR (n = 32; [20]) with clinical graft
dysfunction (greater than 10% increase from baseline serum creatinine
values), and blood samples collected at the time of protocol biopsies with
stable graft function (STA; n = 94). There was an additional phenotype of
samples within the SNSO1 sample set that was not used in the earlier
process of single–center discovery and validation. These were PB collected
at the time of biopsies where the diagnosis was not one of either Banff
graded AR or one of normal renal histology; these samples were codified
nonAR/nonSTA, and consisted of a collection of samples with different
pathologies; n = 72). In this latter category, many samples had clinical graft
dysfunction and the different pathological categories were based on the
centralized biopsy read-outs (12 borderline AR, 37 CAN, 16 CNIT and 7
other pathology).
Evaluation for confounders
To examine if any demographic, clinical or immunosuppression confounders
at baseline or at the time of sampling could have driven the segregation of
the 5-gene set prediction score for AR, 18 different clinical confounders on
the single-center samples were correlated with Q-PCR expression of each
of the 5 genes in the single center data on 81 samples (34 Verification +
47 Training Set) using Pearson correlation. Additionally, we also performed
univariate logistic regression for each clinical confounder with the risk of
AR as well as a multivariate logistic regression model for a combination
of all 18 clinical confounders and 5 genes’ expression values. The con-
founders were posttransplant time, recipient age, recipient gender, donor
gender, donor source, donor age, steroid-free vs. steroid-based immuno-
suppression, total white blood cell count, hematocrit , CMV status, EBV
status, BK virus infection, bacterial Infection, presence of donor-specific
antibodies (DSA), panel reactive antibodies, use of induction therapy (ei-
ther Daclizumab or T cell depleting antibodies), use of calcineurin inhibitors
(tacrolimus or cyclosporine), and use of anti-metabolites (mycophenolate
mofetil or azathioprine).
Results
Cross- platform microarray discovery for AR specific
genes in peripheral blood
From 122 PB, we identified 2382 differentially expressed
genes (false discovery rate; FDR < 5%). All of the
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samples have been deposited at GSE14067 to NCBI
Gene Expression Omnibus (GEO) database. These genes
play a role in leukocyte extravasation, and chemokine,
T cell and B cell receptor signaling (-log10P>1.3; IPA R©;
http://www.ingenuity.com). They are enriched (10x median
intensity across all tissues; http://www.BioGPS.org) (19) in
different blood cells, namely CD8+ T cells (126, p = 3.80e-
16), CD4+ T cells (118, p = 5e-13), CD56+ NK cells (149,
p = 1.3e-9), CD33+ Myeloid cells (150, p = 1.7e-8), Den-
dritic Cells (130, p = 8.8e-8), CD14+ Monocytes (111, p =
1.1e-4), CD34+ cells (119, p = 4.8e-6) and CD19+ B cells
(91, p = 1.6e-3).
Verification of AR specific genes by Q-PCR
We chose 32 genes for QPCR verification (Figure 1A)
that were differentially expressed in all microarray data
sets, and were biologically relevant with enrichment of
cell–specific immune responses in AR. These genes
were DUSP1, IL1RAP, MCM7, NKTR, MAPK9, PSEN1, PT-
PRC, SLPI, STAT1, STAT3, CFLAR, IL32, PBEF1, PHLDA1,
IFNGR1, IL8RA, ITGAX, PLCG1, PTPN11, TNFAIP6, ZAP70,
GOLGA8A, RYBP, TLR8, RNF130, F2RL1, GRZYB, PFN1,
FCGR1A, NFATC3 and IL6R. Given the recent research on
the dual role of FOXP3 in rejection (21,22) and tolerance
(23,24), it was also selected for verification. 15 genes were
significantly differentially expressed between AR and STA
(p-value < 0.05). Out of these 15 genes, five genes (F2RL1,
STAT1, FOXP3, PTPRC and IL6R; p < 0.05) have previously
been shown to be involved in AR. Out of the remaining 10
genes, 8 genes were over-expressed in AR (CFLAR, p =
0.0016; DUSP1,p = 0.0013; IFNGR1, p = 0.0062; ITGAX ,
p = 0.0011; PBEF1, p = 0.00008; PSEN1, p = 0.00007;
RNF130, p = 0.0459; and RYBP, p = 0.0012), and 2 genes
were under-expressed in AR (MAPK9, p = 0.0006; NKTR,
p = 0.0016).
Identification of the minimal discriminative gene set
for AR
We applied logistic regression with best subset selection
to the Verification Set in order to find the minimum number
of genes necessary for the proper classification of biopsy-
confirmed AR(25). Chi-square score for logistic regression
models built using the 10 genes showed that in the data-
set used, using five genes would have the same perfor-
mance as a model using six or more genes. Additional se-
lection criteria were used such as biological relevance and
model performance (high statistical significance 10 p-value
< 0.005 and low standard error of mean [SEM]), resulting
in DUSP1, MAPK9, NKTR, PBEF1, and PSEN1.
Independent validation of the 5 genes in the
single-center training set and building the 5 gene
diagnostic model for AR
Expression of each of the five genes in an independent
Training set of 47 Stanford samples (23 AR, 24 STA) was
also significantly different (p-value < 0.05) (Figure 2A). This
data was used to develop a logistic regression model with a
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Figure 2: Single-center Verification and Validation of Gene Expression for the 5-Gene Set. Box plots of the QPCR gene expression
values are shown for the selected 5 genes: DUSP1, PBEF1 And PSEN1 are upregulated in AR (red outline); NKTR and MAPK9 are
downregulated in AR (green outline) in the single center Verification Set (n = 34; part A) and in the single center independent Training Set
1 (n = 47; part B), for building the logistic regression model on the 5 gene-set. We applied logistic regression with best subset selection
to the Verification Set in order to find the minimum number of genes necessary for the proper classification of biopsy-confirmed AR.
Chi-square score for logistic regression models built using these 10 genes showed that increase in the score was minimal when more
than five genes were used in the model. Chi-square score for logistic regression models built using all 10 genes showed that the increase
in Chi-square score from a model with 1 gene to 3 genes is 7.70; from a model with 3 genes to 5 genes is 1.87; and from a model with 5
genes to a model with 6 is only an increase of 0.48. Hence, the logistic regression model using a set of 5 genes was selected based on
the best performing 5-genes set (Chi-square score = 29.63) as DUSP1, PBEF1, PSEN1, MAPK9, and NKTR. The p values for comparison
of gene expression data for each gene are shown in each dataset and each value is significant (p < 0.05).
penalized maximum likelihood method, which was a more
robust estimation procedure than the usual maximum like-
lihood methods (26,27). In the 5 gene-set model, each of
the regression coefficients describes the size of the con-
tribution of that gene as a risk factor for diagnosing AR,
where the larger the coefficient, the greater the influence
of that gene in AR (Table S1).
Evaluation for confounders
To examine if any demographic, clinical or immunosuppres-
sion confounders at baseline or at the time of sampling
could have driven the segregation of the 5-gene set pre-
diction score for AR, 18 different clinical confounders on
the single-center samples were correlated with Q-PCR ex-
pression of each of the 5 genes in the Training set of 47
samples (23 AR, 24 STA) using Pearson correlation. Uni-
variate logistic regression was also done for each clinical
confounder with the risk of AR as well as a multivariate lo-
gistic regression model for a combination of all 18 clinical
confounders and 5 genes’ expression values. By t-test, all
5 genes had significant change in expression only with the
presence of donor specific antibody (DSA; p < 0.05). By
univariate logistic regression model, all 5 genes were sig-
nificantly associated with AR (p < 0.0001; AUC from 0.829-
0.938) and DSA positivity (p < 0.0001; AUC = 0.828) while
there was no association with the histology grade or C4d
positivity (p = 0.80 for Banff score; p = 0.79 for C4d pos-
itivity). These data thus underscore that the coordinated
expression of the 5-gene set in PB can diagnose AR with
high confidence, irrespective of the differences in patient
characteristics, immunosuppression and rejection timing.
Independent validation of the 5-gene model in the
multi-center SNSO1 sample set
The 5-gene model was validated in a second independent
cohort of 198 samples (Test Set) collected in 12 different
centers as part of the SNSO1 study (Figure 2B). The test
set consisted of PB-biopsy pairs with AR, STA, and an ad-
ditional phenotype of samples within the SNSO1 sample
set that was not used in the earlier process of single–
center discovery and validation. These PB samples were
collected at the time of biopsies where the diagnosis was
not one of either Banff graded AR or one of normal renal
histology; these samples were codified nonAR/nonSTA,
and consisted of a collection of samples with different
pathologies; n = 72; 12 borderline AR, 37 CAN, 16 CNIT
and 7 other pathology.
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Figure 3: Multi-Center Validation of the QPCR Prediction Probability for AR by the 5-Gene Set. A dot plot is shown for individual
percent probability prediction score for AR on 198 independent samples over the course of the 3 year follow-up (time posttransplant in
months on the X-axis) in the SNSO1 multicenter study. Each blood sample is paired with a biopsy for blinded, centralized, histological
diagnosis of the phenotype. Based on the Receiver Operating Characteristic (ROC) curve for the logistic regression model across DUSP1,
PBEF1, PSEN1, MAPK9, and NKTR, a cutoff of h = 0.52 was selected to have the best sensitivity and specificity to discriminate between
AR and STA. In other words, the prediction probability has been derived from the logistic regression model across the 5 genes (Y-axis) and
percent probability prediction score of >52% predicts the sample to have an AR phenotype. In part (A) the 32 AR samples are shown by
red dots, with 3 misclassifications (91% accuracy within class); the 94 STA samples are shown by green dots with 6 misclassifications
(92% accuracy). The ROC curve for AR vs. STA class is shown in part (B). In part (C) the 72 nonAR/nonSTA samples are shown, divided into
4 categories: 12 AR borderline (pink dots), 37 CAN (light blue dots), 16 CNIT (cyan dots) and 7 other diagnoses such as reflux nephropathy
(n = 2), BK nephropathy (n = 1), FSGS recurrence (n = 1) (dark blue dots) and ischemia (n = 3). Within the AR borderline class 4 samples
have <50% prediction scores for AR and misclassify, giving the within class accuracy of 67% (8/12 samples) for borderline AR. The ROC
curve for AR vs. nonAR/nonSTA class is shown in part (D).
The accuracy of the 5-gene model was assessed by eval-
uating the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) on the AR and
STA samples, as well as the AR and non-AR in the Test
Set (Figure 3A). The 5-gene model has 91% sensitivity,
94% specificity, 83% PPV, 97% NPV and 92% accuracy,
to separate AR from STA samples (AUC 0.955; Figure 3B);
and 91% sensitivity, 90% specificity, and 90% accuracy to
separate AR samples from all other phenotypes (STA and
non-AR/non-STA; Figure 3C; AUC 0.937, Figure 3D). It is
important to note that 8/12 of samples from patients clas-
sified as borderline rejection on biopsy were classified as
AR by the 5-gene model (these have been classified as true
negatives in the non-AR/non-STA cohort, but it can be ar-
gued that these samples could also be true positives). The
high prediction of an AR phenotype in the borderline AR
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samples suggests that preclinical injury in AR may also be
identified by Q-PCR analysis of a PB sample and suggest
earlier treatment for the patient.
Discussion
In the current study, we used a cross-platform, high-
throughput, transcript profiling approach to identify a highly
specific, biologically meaningful, concise gene set in PB
whose expression correlates well with the AR/no AR sta-
tus of contemporaneous biopsies collected from the same
patients. A logistic regression model built on a set of 5
genes in PB and extensively validated by Q-PCR, accu-
rately diagnosed rejection, with 91% sensitivity and 90%
specificity, substantially improving on any current available
method for specifically diagnosing AR. Importantly, though
the 5-gene test was developed for a binary comparison of
AR and STA samples, it was validated in an independent
cohort that comprised of samples obtained at 12 different
transplant centers, in patients with varying demograph-
ics and across multiple clinical phenotypes, such as CAN,
CNIT, infection, and acute tubular necrosis, sub-clinical AR,
clinical AR and STA. As the model was built using samples
from a single center, and was validated in an independent
multicenter cohort, general applicability of this test in real-
world appears feasible where the patient population will
contain heterogeneous graft conditions along the contin-
uum from stable to AR.
The SNSO1 trial arbitrarily assigned borderline AR in the
nonAR/nonSTA category, but in retrospect, this might not
have been biologically accurate as most of the “misclassi-
fications” were actually borderline AR, and their inclusion
in the AR group would further enhance the PPV of the
test. This suggests a longer biologic process than previ-
ously thought in immune changes leading to rejection. It
would be important to evaluate serial samples from pa-
tients developing clinical AR episodes to examine if the
5-gene model can detect subclinical acute rejection, that
is, acute rejection prior to its becoming clinically evident.
Some of the Banff graded ARs were borderline (n = 12)
but were scored as AR biopsies in the SNSO1 validation
sample to help compensate for the small number of AR
events (n = 32) that met the conventional AR criteria. Thus
the 5-gene model was used to predict the set of AR and
subclinical borderline AR biopsies in the SNS01 subjects.
Early minimally invasive diagnosis of AR would be a sig-
nificant advance over current practice standards that de-
pend on biopsy for diagnosis and initiation of treatment.
At present, by the time a clinical trigger is available to war-
rant doing a biopsy for rejection diagnosis, the rejection
has evolved with its full humoral or cellular mechanisms.
Having a clinical indication for the rejection episode, based
on the high score on the 5-gene test, that is earlier than a
rise in the serum creatinine, would be a significant advance
for the management of patients, as it would result in the
earlier diagnosis of rejection and provide an early trigger
for performing an indicated biopsy, if warranted. Work is
underway in our group to refine the performance of the
larger gene-set for discriminating cellular from humoral re-
jection, clinically important for discriminating treatment for
AR.
The excellent positive and negative predictive values of
the 5-gene model suggest that a PB test based on these
genes could be useful for screening patients for absence
of AR. Given the excellent discrimination of this test, there
is strong justification for a larger, more definitive follow-up
study with a larger number of AR patients for study, to
evaluate if a higher AR gene score translates into risk of
more aggressive AR or humoral versus cellular AR. The
strong negative predictive value of the model for diagnos-
ing absence of AR opens the door for personalized ther-
apy, where patients can be potentially screened serially by
the 5-gene test, and in the absence of AR risk, have re-
duced follow-up, be candidates to avoid unnecessary pro-
tocol biopsies and, in the presence of graft dysfunction,
be evaluated for alternative etiologies, such as infection,
obstruction or toxicity.
The 5-gene blood test may also provide a new means to
monitor for resolution of AR after treatment intensification.
Additional samples will have to be evaluated from patients
undergoing treatment of AR to examine if immunosup-
pression intensification causes a decrement of the 5-gene
test prediction score, commensurate with histological res-
olution of the AR episode, perhaps guiding assessment of
a patient’s response to therapy.
The PB genes most strongly associated with graft rejec-
tion, do not correlate with multiple demographic, clinical,
treatment modality and bacterial/viral infection parameters.
Although there is significant correlation with DSA positiv-
ity, our model predicts AR, irrespective of cellular or hu-
moral AR. We are further analyzing our data to develop a
blood gene-based model that can further distinguish hu-
moral from cellular rejection. Even though this is a minimal
set of 5 genes for AR classification, expanding out to other
populations may require the inclusion of the 10 gene-set.
The 5 genes are central to leukocyte trafficking and T/B
cell activation, and are mostly expressed in by activated
monocytes in the peripheral circulation, reflecting injury
mechanisms relating to oxidative cellular stress responses
(DUSP1), apoptosis (MAPK9), IL2 dependant activation of
cytolytic genes (NKTR), increased cell adhesion via the e-
cadherin/ catenin complex (PSEN1), and vascular smooth
muscle injury (PBEF1). It is likely that these genes play
a pivotal role in the mechanism of cytolysis and graft mi-
crovasculature injury from activated monocytes in graft re-
jection (28,29) The association of the gene profile of the
selected genes in blood with DSA and peripheral trafficking
of monocytes supports the growing recognition of DSA as
a culprit in graft injury (30,31) and monocytes as primary
culprits in graft dysfunction (32,33).
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Serial performance of the 5-gene test proposed in the
current study suggests a means to stratify patients as
high or low risk for rejections, even in the presence of
other histological injuries in the graft. It may be anticipated
that the more frequent assessment of risk afforded by
the minimally invasive nature of this assay will facilitate
more prompt therapeutic management which may alter the
course of rejection, providing a critical, and as yet unavail-
able, new dimension of immunosuppression customiza-
tion for a transplant patient. However, a couple of caveats
should be noted. The sample numbers in the discovery set
are limited, but are offset by the power of validating the
discovery in the SNSO1 multicenter study. As this study
was performed in children and young adults, the nature of
the rejection may be more aggressive due to either the
size mismatch of adult-sized organ and infant recipient, or
the higher rate of treatment nonadherence adolescent re-
cipient, both of which could result in stronger immune re-
sponse signal. Additionally, none of the pediatric patients in
this study received induction with anti-CD52 depletion ther-
apy or with co-stimulatory blockade. Therefore, the perfor-
mance of the 5-genes model should be further studied for
its potential to diagnose rejection in patients of all ages, in
larger sample cohorts and in different immunosuppressive
regimens. The empirical results of the diagnostic potential
of the selected 5-gene panel in this study suggest poten-
tial clinical utility and support the future development of
a prospective clinical trial in children and extension of this
work in adult renal transplant recipients to confirm clinical
application.
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Supporting Information
The following additional supporting information may be
found in the online version of this article:
Table S1. Patient Demographics for all PB samples in-
cluded in the microarray and Q-PCR studies. P values for
age and posttransplant time were calculated using the T
test with unequal variance. Probabilities of steroid usage,
gender and donor source were calculated using Chi-Square
analysis.
Please note: Wiley-Blackwell is not responsible for the con-
tent or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material)
should be directed to the corresponding author for the
article.
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